Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body

A submission seeks to expand Ameluz’s label beyond the face and scalp to treatment fields of up to approximately 240 cm² on other areas of the body, using an adjusted illumination protocol. The text gives no regulatory decision or timeline.